Tecartus
mayo 10, 2022
INTRODUCTION Tecartus is a new advanced therapy approved to treat adults with mantle cell lymphoma (MCL)¹. This disease is a lymphatic system cancer. Specifically, it
Menú
leaders in
advanced
therapies
We are a leading company in the field of research and development of advanced therapies. Although we are a young company in the pharmaceutical industry, we have established a solid reputation for our commitment to quality and efficiency in the conduct of clinical trials.
In conclusion, Geistek Pharmaceuticals is a leading company in the field of drug research and development, with a highly qualified and experienced team and a commitment to ethics and transparency. For these reasons, Geistek is the best choice for conducting a clinical trial.
PROFESSIONALISM
One of the reasons why Geistek is the best choice to conduct a clinical trial is our highly trained and experienced team of investigators. All members of the Geistek team are highly qualified professionals with extensive experience in the design and execution of clinical trials. In addition, we have an extensive network of collaborators and partners around the world, giving us access to a wide range of patients and high quality research sites.
TRANSPARENCY
Another reason why Geistek is an excellent choice for a clinical trial is its commitment to ethics and transparency. Geistek adheres to strict ethical standards and complies with all applicable regulations and standards in each of the countries where it conducts its clinical trials. In addition, Geistek strives to maintain high standards of transparency and communication with all stakeholders, including patients, investigators and regulatory authorities.
WE WORK WE INNOVATE WE DESIGN WE STUDY WE CREATE WE DREAM
FOR Him Her US YOU ALL
oUR SERVICES
Why work with us?
QUALITY
We are a company founded in 2020, which means that we have a young and highly qualified team that is always ready to work on innovative projects.
CUSTOMIZED
We offer a wide range of services from clinical trial monitoring to statistical exploitation of research projects. We are sure you will find in Geistek Pharmaceuticals the solution you need.
WARMS
Our team of experts is always ready to help you get the most out of our platform and to ensure that your projects are carried out optimally.
INNOVATORS
We are a CRO (Contract Research Organization) expert in advanced therapies. Our team has extensive experience in this field and is highly qualified to carry out clinical trials and research projects efficiently and reliably.
COMMITED
We have exceptional customer service and are ready to help you at all times. We are committed to making your experience with Geistek Pharmaceuticals the best it can be!
WE ARE THE NEXUS
Throughout the development of a new drug, many entities participate with complementary value propositions and through collaborations that might establish very beneficial synergies for both institutions.
Geistek has agreements with more than 500 investment funds and private investors interested in advanced therapies. In addition, it currently works with a large volume of top-level biotechnological and pharmaceutical companies and research centres that carry out their activity in the design and development of this kind of therapies.
Due to the extensive networking that we have, we consider ourselves a key nexus to give the boost that biotechnological and pharmaceutical companies need in the development of their advanced therapies.
Latest news
KYMRIAH, AN ANTI-CD19 CAR-T THERAPY
abril 19, 2022
INTRODUCTION Kymriah (Novartis) is an advanced therapy medicine that belongs to the gene therapyproduct category. It is approved for B-cell acute lymphoblastic leukemia (ALL) in
Carvykti™, the new advanced therapy approved by FDA
marzo 20, 2022
INTRODUCTION ¹. CARVYKTI™ (ciltacabtagene autoleucel – Johnson & Johnson) was approved by the U.S. Food and Drug Administration (FDA) in February 2022 for the treatment
Contact us
